Bausch & Lomb Corp

Overview

Bausch + Lomb is a global eye-health company whose business spans Vision Care, Pharmaceuticals and Surgical. Its products include contact lenses and lens-care products, over-the-counter eye drops and vitamins, prescription and generic eye medicines, and ophthalmic devices, equipment and lenses used in surgery.[1]

The company’s stated mission is to “help people see better to live better, all over the world.” [2] Founded in 1853, it reports a presence in approximately 100 countries and approximately 13,500 employees.[3][4]

Bausch + Lomb reported $5.101 billion in revenue for 2025.[5] Its latest available interim results at the time of this research reported $2.638 billion in revenue for the six months ended June 30, 2026.[6] [1]+5

Products & services

Bausch + Lomb’s Vision Care products include daily-disposable and frequently replaced contact lenses, including INFUSE, Biotrue ONEday, PureVision, SofLens and ULTRA. Its consumer eye-care range includes Biotrue and Renu lens-care solutions, Boston cleaning and conditioning products, and drops and supplements under brands such as Lumify, Soothe, Artelac, Alaway, Mioclear, Blink, PreserVision and Ocuvite. The company reports that 2025 Vision Care revenue comprised 65% consumer eye care and 35% contact lenses.[1]+2

Its Pharmaceuticals portfolio includes proprietary and generic ophthalmic products for conditions such as dry eye, glaucoma, ocular hypertension, inflammation and retinal disease. Named products include MIEBO, an ophthalmic solution used to target tear evaporation in dry-eye disease; XIIDRA, a non-steroid eye drop for dry-eye signs and symptoms; and VYZULTA, a treatment for glaucoma and ocular hypertension.[9]+2

Surgical products include intraocular lenses (IOLs), delivery systems, phacoemulsification equipment and instruments for cataract, corneal, vitreous and retinal procedures. IOL brands include Akreos, enVista, Crystalens and Trulign; enVista offerings include Aspire, Envy and toric lens options. The Stellaris Elite platform is used in cataract and retina surgery; listed capabilities include Adaptive Fluidics, Attune Energy and a nominal 28.5 kHz phaco frequency for cataract procedures, and a Bi-Blade cutter and wireless dual-linear foot pedal for retina procedures. Diagnostics include ScoutPro, a portable tear-osmolarity instrument, and an in-office ocular-allergy diagnostic system.[12]+6

For 2025, reported revenue was $2,923 million in Vision Care, $1,284 million in Pharmaceuticals and $894 million in Surgical, out of $5,101 million total revenue. The company does not report a distinct standalone services segment in the cited annual product breakdown.[8][6] [1]+13

Geographic presence

Bausch + Lomb is headquartered in Vaughan, Ontario, Canada, and also identifies Bridgewater, New Jersey, as its U.S. headquarters. Its 2025 Form 10-K describes a footprint of manufacturing plants and other properties in Mexico and in countries across Europe, the Middle East, Asia and South America. The company reports operating in approximately 100 countries, with 24 global facilities supporting manufacturing and about 13,000 employees across global research and development, manufacturing and commercial teams; it does not disclose employee counts by geography.[19]+2

Principal properties listed in the 2025 Form 10-K include corporate and distribution facilities in Vaughan; administration in Bridgewater; offices, research and development, or manufacturing in Rochester, New York; Waterford, Ireland; Jinan and Beijing, China; Berlin and Eppelheim, Germany; Aubenas, France; Macherio, Italy; Tampa and Clearwater, Florida; St. Louis, Missouri; and Greenville, South Carolina. The company also lists distribution in Woodruff, South Carolina, and offices and distribution in Lynchburg, Virginia.[22]

Bausch + Lomb sells through its own sales force and wholesalers, and in some markets directly to physicians, hospitals and large drugstore chains; it uses distributors in markets where it lacks its own sales staff. Its markets include the United States, Canada, Europe, Asia, Latin America, the Middle East and Africa. The 2025 filing says approximately 3% of revenue came from products sold in Russia, Ukraine and Belarus; it does not provide a comprehensive country- or region-level revenue breakdown.[23]+2 [19]+6

Business segments

For fiscal 2025, Bausch + Lomb reported three segments. Vision Care focuses on contact lenses and consumer eye care, including lens-care products, over-the-counter eye drops, and eye vitamins; segment revenue was $2.923 billion, approximately 57% of consolidated revenue.[1][5] Pharmaceuticals comprises proprietary and generic medicines, including treatments for post-operative care and conditions such as glaucoma, inflammation, ocular hypertension, dry eye, and retinal disease; revenue was $1.284 billion, approximately 25%.[1][5]

Surgical focuses on ophthalmic surgical equipment, instruments, devices, and consumables for procedures involving cataracts, the cornea, vitreous, and retina; products include intraocular lenses and delivery systems and phacoemulsification equipment. Revenue was $894 million, approximately 18%.[1][5] Shares are approximate, calculated from the segments’ combined $5.101 billion of reported revenue. The 2026 second-quarter filing continues to report Vision Care, Pharmaceuticals, and Surgical as the company’s segments.[6] [1]+8

Company history

Bausch + Lomb was founded in Rochester, New York, in 1853, when John Jacob Bausch opened an optical-goods shop with financial backing from Henry Lomb, who later became his partner. The company expanded into microscope production in 1875 and made Ray-Ban aviator goggles for military pilots in 1936. In 1971, it launched SofLens, which the company describes as the first mass-produced soft contact lens in the United States.[3]

In 1997, Bausch + Lomb expanded into ophthalmic surgery by acquiring Storz Ophthalmics and Chiron Vision. Valeant Pharmaceuticals agreed to acquire the company in 2013 and completed the acquisition that August, making Bausch + Lomb a Valeant division.[3]+2

Bausch + Lomb began trading publicly on the NYSE and TSX in May 2022, while remaining majority-owned by Bausch Health.[28] In 2023, it acquired Johnson & Johnson Vision’s Blink eye- and contact-lens-drop product line and Novartis’s XIIDRA and related ophthalmology assets, broadening its eye-care and dry-eye businesses.[29][14] [28]+5

Sources

• Bausch & Lomb Corp — Full financial report (2025 Y)
  17 citations

  [1][5][7][8][9][10][12][13][14][15][19][22][23][24][25][28][29]
• www.bausch.com[2]
• www.bausch.com[3]
• ir.bausch.com[4]
• Bausch & Lomb Corp — Full financial report (2026 Q 2)[6]
• www.bausch.com[11]
• www.bausch.com[16]
• www.bauschsurgical.com[17]
• www.bauschsurgical.com[18]
• www.bausch.com[20]
• www.bausch.com[21]
• ir.bauschhealth.com[26]
• ir.bauschhealth.com[27]